
Azimuth Drugs And Pharmaceuticals Private Limited
Manufactures chemicals, compounds, and pharmaceuticals since 2010 in Kerala.
Manufactures chemicals, compounds, and pharmaceuticals since 2010 in Kerala.
Azimuth Drugs And Pharmaceuticals Private Limited (ADAPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 February 2010 and has a history of 15 years and two months. Its registered office is in Kozhikode, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹1.43 Cr.
Parambath Sajeesh, Anilkumar, Mariammanzil Fasel, and Fifteen other members serve as directors at the Company.
Kozhikode, Kerala, India
+91-XXXXXXXXXX
U24233KL2010PTC025508
025508
Private Limited Indian Non-Government Company
16 Feb 2010
30 Sep 2022
31 Mar 2022
Unlisted
Roc Ernakulam
Name | Designation | Appointment Date | Status |
---|---|---|---|
Parambath Sajeesh ![]() | Additional Director | 15-Feb-2014 | Current |
Anilkumar ![]() | Additional Director | 15-Feb-2014 | Current |
Mariammanzil Fasel ![]() | Additional Director | 15-Feb-2014 | Current |
Ismail Veettil ![]() | Additional Director | 15-Feb-2014 | Current |
Kuzhichalil Kumar ![]() | Additional Director | 15-Feb-2014 | Current |
Valiyaparambil Hamsath ![]() | Additional Director | 15-Feb-2014 | Current |
Azimuth Drugs And Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 53.39% decrease in profit. The company's net worth observed a substantial decline by a decrease of 33.75%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2017, Azimuth Drugs And Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Muhammad Saleena and Saseendran Thundiyil are mutual person
Ahamed Puthukkidi is a mutual person
Parambath Sajeesh, Valiyaparambil Hamsath and 5 more are mutual person
Parambath Sajeesh, Anilkumar and 16 more are mutual person
Manalpurathu Kunhahammad is a mutual person
₹1.43 Cr
₹0
Date | Lender | Amount | Status |
---|---|---|---|
20 May 2022 | Hdfc Bank Limited | ₹1.43 Cr | Open |
Unlock and access historical data on people associated with Azimuth Drugs And Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Azimuth Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Azimuth Drugs And Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Azimuth Drugs And Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2022 as per latest MCA records.
A charge with Hdfc Bank Limited amounted to Rs. 1.43 Cr with Charge ID 100590620 was registered on 20 May 2022.
Azimuth Drugs And Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2022 with Roc Ernakulam.
Parambath Thazhakuniyil Sajeesh was appointed as a Additional Director was appointed as a Additional Director on 15 Feb 2014 & has been associated with this company since 11 years 2 months .
Anilkumar was appointed as a Additional Director was appointed as a Additional Director on 15 Feb 2014 & has been associated with this company since 11 years 2 months .
Mariammanzil Muhammed Fasel was appointed as a Additional Director was appointed as a Additional Director on 15 Feb 2014 & has been associated with this company since 11 years 2 months .
Azimuth Drugs And Pharmaceuticals Private Limited was incorporated on 16 Feb 2010.
The authorized share capital of Azimuth Drugs And Pharmaceuticals Private Limited is ₹ 2.50 Cr and paid-up capital is ₹ 0.30 M.
Currently 18 directors are associated with Azimuth Drugs And Pharmaceuticals Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Azimuth Drugs And Pharmaceuticals Private Limited is H No 4/110 Chaithanya House Mandarathoor Via, Kozhikode Dt India, Vatakara, Kerala, 673105.
The corporate identification number (CIN) of Azimuth Drugs And Pharmaceuticals Private Limited is U24233KL2010PTC025508 and the company number is 025508 as per Ministry of Corporate Affairs (MCA).
The financial reports for the fiscal year 2017 indicates that The net worth of Azimuth Drugs And Pharmaceuticals Private Limited has experienced an downturn of -33.75%.
As per the financial statements for fiscal Year 2017, The total open charges for Azimuth Drugs And Pharmaceuticals Private Limited amount to ₹ 1.43 Cr.
The most recent Balance Sheet for Azimuth Drugs And Pharmaceuticals Private Limited was filed with the ROC on 31 Mar 2022.
Search company & director profiles for free and gain access to critical business data.
PS
IV